Kevin Kunzmann

The second process of ARU-1801 in a new patient resulted in up to 4 times greater engraftment of transduced hematopoietic stem cells and progenitors at 6 months.

An interview with a Janssen expert on the growing portfolio and newest data for daratumumab.

The sickle cell disease subtype is associated with increased risk among patients as young as 2 years old.

The last episode of 2020 caps advances and ongoing research into the most burdensome chronic respiratory disease in the US.

The new findings show worsened outcomes among particular comorbid patient groups, as well as minority patients.

A discussion on what the future of monitoring the rare disease may entail, and how COVID-19 interrupted in-person assessment earlier this year.

The combination therapy was linked to a record phase 3 progression-free survival rate among a subpopulation of patients with the rare cancer.

A discussion with a study author and longtime expert on improving monitoring of the rare disease.

The furthest-progressed gene-edited therapy for a genetic disease reported historic efficacy data in ongoing phase 1/2 trials.

New data from an ongoing trial showed patients achieved MRD negative status after a vaccine regimen—and have maintained status over a year.

Early assessment from an Australian team of investigators is targeting a pathway linked to hemoglobin expression.

The indication is based on 48-week results showing significant benefit in reduced HAE attacks among pediatric and adult patients.

If approved, the vaccine may become available to the US public as early as December 21st.

Patients with late-onset asthma and allergies had an increased risk of COPD as well as a heightened risk of landing in the “multiple disorders” comorbidity profile.

The indication comes from collaborative work among experts and community leaders coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.

The newest indication coincides with growing concerns that COVID-19 and flu spread will cause unprecedented burden on the US this winter.

The Regeneron monoclonal antibodies are linked to reduced risk of hospitalization or ED visit among mild-to-moderate COVID-19 cases.

An interview with a pain specialist on advancing alternative pain therapy options.

Lonafarnib was linked to improved mortality over a maximum of 11 years follow-up, according to supporting data.

The first-line atypical antipsychotic was linked to better outcomes in patients than comparators aripiprazole and olanzapine.

Lung cancer interception research and strategies are trying to make up ground on the often-missed risk group.

Newborns who were given a probiotic had lower rates of atopic dermatitis and lower symptom scores, according to a new study.

A team of researchers share strategies to "map out" pre-cancer lung risks in their greater goal of interception.

Preliminary data from a phase 3 trial has met its trigger point in total COVID-19 infections, and the interim findings look good for mRNA-1273.

RD surgery and scleral buckle appear to be preferred among ophthalmologists—but are linked to further necessary care in children.

Retinal nerve fiber layer density also appears to be influenced by presentation of both conditions.

A new trial shows treatment-naive patients with nAMD have similar BCVA and safety outcomes with the biosimilar.

Data show patients can decrease annual injections while retaining, if not improving, on BCVA scores over 104 weeks.

New findings suggest the common ophthalmic disorder in premature infants could be three-fold more prevalent in multiracial infants.

New AAO 2020 findings suggest even geographical differences could define retinal detachment risks among nearsighted patients.